<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201102049234N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-26</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Functional Electrical Stimulation Intervention in Treatment of Older Adults with COVID-19</public_title>
      <acronym>COVID-19</acronym>
      <scientific_title>The Effect of Functional Electrical Stimulation Intervention on Fatigue, Muscle Strength, Muscle Mass and Quality of Life in Older Adults with COVID-19</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58793</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization with a random number table such that each person is given a code and they are written in a table. We select one place from the table in a blinded manner. Then we select 12 numbers smaller than the selected number in the same row. The same would be true for the treatment and control group, Blinding description: The researcher will be blind to the intervention using the research assistant and he/she is absent in the treatment room. The outcome evaluator will vary with the researcher and research data be given him with code and is unaware of the participants intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Coronavirus disease (COVID-19).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first group will receive functional electrical stimulation during 10 sessions of rehabilitation treatment. The patient will sit on a chair. FES will apply bilaterally using an electrical stimulator (710 P-plus, Iran) with pairs of electrodes (10 × 5 cm) placed transversally on the quadriceps muscle (5 cm below the inguinal crease and 5 cm above the patella). The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 μs). The total duration of the FES session is 30 minutes. Thus eliciting a total of 90 evoked contractions per day. Stimulation intensity will adjust daily by the physical therapist to elicit a visible twitch in each muscle. The maximal stimulation intensity will record for each session and considered as a surrogate marker of FES dose. The patient will sit on a chair. FES will apply bilaterally using an electrical stimulator with pairs of electrodes (10 × 5 cm) placed transversally on the anterior tibialis muscle. One electrode will place over the motor point of the TA muscle and the other will place immediately below the belly of the muscle. FES will be apply for 20 minutes (pulse duration μs) with a frequency of 50 Hz. Intervention 2: Control group: The second intervention group will receive sham functional electrical stimulation during 10 sessions of rehabilitation treatment. Sham FES will follow the same procedures, but the device will switch on only for the initial 20 seconds, with the current then diminish to zero. The patients will inform of the possibility of feeling a slight initial tingling that would either diminish, disappear or continue during the 20-minute session.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There are not more informations</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fariba Ramezani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Neuromuscular Rehabilitation Research Center, Tabatabaee Clinic, Qods Blvd., Semnan</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3519618375</zip>
        <telephone>+98 23 8502 3332</telephone>
        <email>mona.ramezani.sa@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Ehsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Neuromuscular Rehabilitation Research Center, Tabatabaee Clinic, Qods Blvd., Semnan</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3519618375</zip>
        <telephone>+98 23 8502 3332</telephone>
        <email>fatemehehsani59@yahoo.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elderly People with COVID-19 After Hospital Discharge
Age Over 60 Years
Obvious Atrophy of the Quadriceps and Tibialis Anterior Muscles
Normal Level of Alertness ,Orientation and Responsiveness to Verbal Stimulus
To Be Willing to Participate in the Study</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Known or Suspected Malignancy in the Lower Limb
Body Mass Index Equal or Greater than 35 Kilogram Per Square Meter
Conditions Preventing Electrical Stimulation Treatment for Example Deep Vein Thrombosis and Rhabdomyolysis
Skin Lesions at the Site of Electrical Stimulation
Diagnosis of Alzheimer's Disease, Degenerative Disease and Polyneuropathy
Conditions Preventing Outcome Assessment  for Example Amputation or Inability to Walk
Presence of an Implanted Cardiac Pacemaker or Defibrillator</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U07.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>COVID-19, virus identified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group will receive functional electrical stimulation during 10 sessions of rehabilitation treatment. The patient will sit on a chair. FES will apply bilaterally using an electrical stimulator (710 P-plus, Iran) with pairs of electrodes (10 × 5 cm) placed transversally on the quadriceps muscle (5 cm below the inguinal crease and 5 cm above the patella). The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 μs). The total duration of the FES session is 30 minutes. Thus eliciting a total of 90 evoked contractions per day. Stimulation intensity will adjust daily by the physical therapist to elicit a visible twitch in each muscle. The maximal stimulation intensity will record for each session and considered as a surrogate marker of FES dose. The patient will sit on a chair. FES will apply bilaterally using an electrical stimulator with pairs of electrodes (10 × 5 cm) placed transversally on the anterior tibialis muscle. One electrode will place over the motor point of the TA muscle and the other will place immediately below the belly of the muscle. FES will be apply for 20 minutes (pulse duration μs) with a frequency of 50 Hz.</i_keyword>
      <i_keyword>Control group: The second intervention group will receive sham functional electrical stimulation during 10 sessions of rehabilitation treatment. Sham FES will follow the same procedures, but the device will switch on only for the initial 20 seconds, with the current then diminish to zero. The patients will inform of the possibility of feeling a slight initial tingling that would either diminish, disappear or continue during the 20-minute session.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fatigue. Timepoint: Before the intervention and after the end of intervention. Method of measurement: Chalder fatigue questionnaire.</prim_outcome>
      <prim_outcome>Muscle Strength. Timepoint: Before the intervention and after the end of intervention. Method of measurement: Biofeedback pressure device.</prim_outcome>
      <prim_outcome>Muscle Mass. Timepoint: Before the intervention and after the end of intervention. Method of measurement: Ultrasonographic device.</prim_outcome>
      <prim_outcome>Quality of Life. Timepoint: Before the intervention and one month after the start of intervention. Method of measurement: WHOQOL-BREF questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-28</approval_date>
        <contact_name>Ethics committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Headquarters of Semnan University of Medical Sciences, Basij Blvd., Semnan Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
